A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
This is a study to evaluate the efficacy and safety of TQB2450 injection combination with Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
DRUG: TQB2450|RADIATION: Intensity modulated radiotherapy
Overall response rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., up to 48 weeks
Disease control rate（DCR）, Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 48 weeks|Duration of Response (DOR), The time when the participants first achieved complete or partial remission to disease progression., up to 48 weeks|Progression-free survival (PFS), PFS defined as the time from first dose until the first documented progressive disease (PD) or death from any cause., up to 48 weeks|12-month progression-free survival rate, 12-month PFS defined as the time from first administration until the first documented progressive disease (PD) or death from any cause within 12 months., up to 48 weeks|12-month survival rate, 12-month survival rate defined as the time from first administration to death from any cause within 12 months., up to 48 weeks|24-month survival rate, 24-month survival rate defined as the time from first administration to death from any cause within 24 months., up to 96 weeks|Local regional recurrence-free survival (LRRFs), The time interval between the patient's first medication and the appearance of local imaging progress., up to 48 weeks|Distant metastasis-free survival (DMFS), The time interval between the patient's first medication and the appearance of distant metastasis imaging progression or death., up to 48 weeks|Overall survival (OS), OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 96 weeks
This is a study to evaluate the efficacy and safety of TQB2450 injection combination with Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal carcinoma.